Support PenkeMerck & Company Inc - Trending symbols
Latest News of Merck & Company Inc
| Date | Title | Read |
|---|---|---|
| 2025-09-11 19:42 | Merck (MRK) Announces Positive Phase 3 Results For 21-Valent Pneumococcal Vaccine | Read |
| 2025-09-10 20:33 | US drugmaker scraps plans for £1bn UK research centre | Read |
| 2025-09-10 06:59 | Guggenheim Initiates Summit Therapeutics (SMMT) With a Buy Rating | Read |
| 2025-09-05 20:17 | Companies tap US bond market for nearly $70 billion, starting September on a busy note | Read |
| 2025-09-05 11:50 | Lyophilized Injectable Drugs Market Report 2025-2033 | R&D Efforts to Improve Safety and Reconstitution Time, Alongside Expanding CDMO Services and Emerging Market Contributions | Read |
| 2025-08-20 20:59 | Veeva Systems Q2 Results Likely In-Line to Better, Maintain H2 Outlook, Truist Says | Read |
| 2025-08-19 19:29 | Merck (MRK) Antibody Drug Ifinatamab Deruxtecan Gains Breakthrough Therapy Designation | Read |
| 2025-08-19 17:37 | MRK's ADC Candidate Gets FDA Breakthrough Therapy Tag for Lung Cancer | Read |
| 2025-08-17 08:30 | Merck & Co., Inc. (MRK) Announces Update on Phase 3 KEYNOTE-905 Trial | Read |
| 2025-08-14 01:05 | China pharma firms turn to local reagent suppliers to cut costs and delivery times | Read |
Notifications
| Type | Notification | Date |
|---|---|---|
| RSI Overbought | Overbought RSI (Relative Strength Index) | 2025-09-09 |
Trends
| 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Total Other Income Expense Net | 168,444,500 | 268,945,000 | 437,389,500 | -431,727,500 | 5,662,000 | 234,973,000 | 240,635,000 | -689,348,500 | -448,713,500 | |
| Tax Provision | 440,797,500 | 293,865,000 | 734,662,500 | -167,414,000 | 567,248,500 | 207,486,500 | 774,735,000 | -1,504,945,000 | -730,210,000 |
Comments
How you think about this?